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Eli: When Myriad Genetics Prohibited a Myriad of Options: Association

WHEN MYRIAD GENETICS PROHIBITED A
MYRIAD OF OPTIONS:
ASSOCIATION FOR MOLECULAR PATHOLOGY V.
USPTO'
"The useful properties of a gene's sequence . . . are

not ones that scientists have invented, but instead,
are natural, inherent properties of the genes
themselves." 2

I. INTRODUCTION

One of the "most controversial areas on patentable subject
matter" arises from the issuance of patents for research or
innovation directly related to biological material, such as genetic

1. This case note is a follow up to last spring's article in the Journal for Art,
Technology, and Intellectual Property entitled "Come, Let Us Return to
Reason" by Lauren M. Dunne. Ms. Dunne's case note described and analyzed
the Association of Molecular Pathology's case against the USPTO while the
case was still in its pleading phase. The note focused on the complaint and the
preliminary motions and arguments made by each side. The case has since been
decided in the Southern District of New York and this note now analyzes the
court's opinion.
While Ms. Dunne advocated the practice of granting patents on isolated DNA
and argued for the side of the USPTO, this note instead argues for Plaintiffs,
named in the case as the Association of Molecular Pathology. Ms. Dunne
argued that gene patents have not inhibited research and that the arguments in
support of the complaint against the USPTO and Myriad need to focus
specifically more on practical matters and less on philosophical grounds. In
opposition, this note uses the statutory language and the judicially created
products of nature exception to patentable subject matter to support Plaintiffs'
philosophical arguments. See Lauren M. Dunne, "Come, Let Us Return to
Reason": Association of Molecular Pathology v. USPTO, 20 DEPAUL J. ART
TECH. & INTELL. PROP. L. 473 (2010).

2. Lori B. Andrews, Genes and Patent Policy: Rethinking Intellectual
PropertyRights, NATURE REVIEWS, Oct. 2002, at 803.
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This controversy stems from
material or living organisms.
conflicting viewpoints over the United States Patent and
Trademark Office's (USPTO)4 policy and practice of granting
patents on human hormones,' cellular proteins,' and genetically
engineered animals, 7 to name a few.' Since 1982, the USPTO has
extended the practice and has issued patents directed to isolated
DNA sequences. A particular ongoing controversy involves the
pharmaceutical giant Myriad Genetics9 who in the 1990s obtained
patents on the BRCA 11o and BRCA2" gene sequences.
The BRCAl and BRCA2 genes, collectively known as
BRCAl/2, are often called the "breast cancer genes" because
mutations in these genes correlate with an increased risk in breast
cancer and ovarian cancer in women. 2 Breast cancers arising from
3. 1 Donald S. Chisum, Chisum on Patents § 1.02 [7] (2009).
4. The USPTO is the Federal agency for granting U.S. patents and registering
trademarks. See The USPTO: Who We Are, http://www.uspto.gov/about/
index.jsp (last visited Feb. 14, 2011).
5. U.S. Patent No. 4,652,525 (filed June 28, 1983) (Recombinant Bacterial
Plasmids Containing the Coding Sequences of Insulin Genes).
6. U.S. Patent No. 6,262,098 (filed August 6, 1999) (Estrogen Receptor
Modulator protein).
7. U.S. Patent No. 4,736,866 (filed June 22, 1984) (the Harvard University
Oncomouse).
8. See generally BIOTECHNOLOGY INDUSTRY ORGANIZATION, GUIDE TO
BIOTECHNOLOGY 2008 (2008), http://bio.org/speeches/pubs/er/BiotechGuide
2008.pdf.
9. Myriad Genetics is a healthcare company founded in May 1991
specializing in developing and marketing molecular diagnostic products to
perform such tasks as assessing a person's risk of developing a disease later in
life. See Myriad Genetics - About, www.myriad.com/about (last visited Feb.
14, 2011). "Myriad is a for-profit corporation located in Salt Lake City, Utah
[that does] business throughout the United States. Myriad is incorporated in
Delaware. Myriad is a co-owner of patent 5,747,282, and formerly was a coowner of several of the other patents challenged [by the Association for
Molecular Pathology]." Complaint at 13, 128, Ass'n for Molecular Pathology v.
U.S. Patent & Trademark Office, No. 09-4515 (S.D.N.Y. filed May 12, 2009),
http://docs.justia.com/cases/federal/district-courts/new-york/
available at
nysdce/1:2009cv04515/345544/1 [hereinafter Compl.]. At the time of the case,
Myriad had an exclusive license on all of the patents challenged in the case. Id.
10. U.S. Patent No. 5,747,282 (filed June 7, 1995).
11. U.S. Patent No. 5,710,001 (filed Dec. 21, 1995).
12. These patents are directed to isolated and purified human genes,
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mutations in a person's BRCA1 and BRCA2 genes account for
between 5% and 10% of all breast cancers." The lifetime risk for
ovarian cancer is about 55% for women with BRCA1 mutations
and about 25% for women with BRCA2 mutations.14
As the exclusive licensee of the BRCAl and BRCA2 gene
patents, Myriad Genetics' right to commercialize the BRCAl/2
diagnostic screening test for genetic mutations ultimately gave
Myriad control over all BRCA1/2 testing in the United States, for
which it charged more than $3000 per test." Until the decision in
Associationfor MolecularPathology v. USPTO, Myriad precluded

competitors from developing alternative BRCAl/2 screening tests
in the United States. This exclusion prompted concerns in the
genetic and breast cancer research community that Myriad's patent
rights could impede research and innovation, resulting in a
complex debate over the continued practice of granting patents
directed to isolated DNA and the appropriate measures to balance
the reward for technological advancement with the prevention of
societal harm.' 6
mutations in those genes, and correlations between those mutations and an
increased risk of breast or ovarian cancer. See U.S. Patent No. 5,747,282 (filed
June 7, 1995); U.S. Patent No. 5,710,001 (filed June 7, 1995). The BRCAl
sequence is found on chromosome 17 while the BRCA2 sequence is found on
chromosome 13. J A Duncan et al., BRCAI and BRCA2 Proteins: Roles in
Health and Disease, 51 J CLIN PATHOL: MOL PATHOL 237, 237-38 (1998).
These genes code for proteins that are thought to be critical for DNA repair and
transcription regulation. Id. Inactivation of the gene is caused through
mutation, altering the protein and leading to abnormal cellular gene expression.
Id
13. Robert Cook-Deegan et al., Impact of Gene Patents and Licensing
Practices on Access to Genetic Testing for Inherited Susceptibility to Cancer:
Comparing Breast and Ovarian Cancers with Colon Cancers, 12 GENET MED
S15, S19 (2010).
14. Id.
15. Gina Shaw, New York Court Knocks Out Gene Patents; What's Next?,
NEUROLOGY TODAY, June 17, 2010, at 33.
16. Mildred K. Cho et al., Effects of Patents and Licenses on the Provisionof
Clinical Genetic Testing Services, 5 JOURNAL OF MOLECULAR DIAGNOSTIcs, 38 (2003). Survey results indicate that 53% of laboratory directors in the United
States actively decided to cease the development of new clinical tests because of
a gene patent or license. Id. at 5. Sixty-seven percent of these laboratory
directors believed that gene patents decreased their ability to conduct research.
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The controversy surrounding the patentability of isolated DNA,
such as the patents held by Myriad, is certainly not new. While
patent attorneys have successfully found ways to continue
obtaining patents for their clients regardless of the conflict, the
complaint drafted by the American Civil Liberties Union (ACLU)
against Myriad" in May of 2009 contesting the validity of its
patents "further polarized the already divisive issue."" The ACLU
sought to invalidate the USPTO practice of granting patents to
isolated DNA, a practice that the USPTO adopted nearly thirty
years ago.
As will be discussed in this Note, a court has now ruled for the
first time that isolated DNA sequences are not patentable subject
matter. '9
While many parties had numerous reasons for
supporting the invalidation of Myriad's BRCAl and BRCA2
patents, the Southern District of New York in Association for
Molecular Pathology v. USPTO avoided any comment on the
societal and scientific harms of the patents and focused instead
only on resolving the case on statutory grounds. 20 This is
problematic. The patenting of isolated DNA causes inexcusable
and intolerable societal harm warranting its exclusion from patent
protection on a deeply fundamental and equitable basis. While the
above decision properly invalidated Myriad's BRCA 1/2 patents as
improperly directed at non-patentable subject matter under 35
U.S.C. § 101,21 a rather technicality-based holding, the court
practically ignored several of the equitable and policy based
arguments set forth by Plaintiffs and their amici. This is not to say
that it was improper for the court to apply § 101 and the "products
of nature" exception to hold that isolated DNA was not patentable
subject matter. Nevertheless, the court's exclusive focus on a
Id. at 7.
17. Compl., supra note 9.
18. Dunne, supra note 1, at 475.
19. Ass'n for Molecular Pathology v. USPTO, No. 09 Civ. 4515 (RWS),
2010 U.S. Dist. LEXIS 35418, at *110 (S.D.N.Y. April 2, 2010).
20. Id.
21. Section 101 provides: "Whoever invents or discovers any new or useful
process, machines, or composition of matter, or any new and useful
improvement thereof, may obtain a patent therefore, subject to the conditions
and requirements of this title." 35 U.S.C. § 101 (2006).
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technical resolution of the case ignores the myriad of policy
arguments presented by Plaintiffs and their amici. The court
subsequently failed to provide any guidance to the American
patent system and the USPTO's practices with regard to the
appropriate weight to give policy and societal concerns to
invalidate a patent that plainly creates more harm than good for
society as a whole. Most troublingly, the court deferred any
discussion or analysis of Plaintiffs' argument that certain patents
do not foster the constitutional purpose of science working for the
betterment of society, leaving such an essential issue
disappointingly unresolved and seemingly undervalued in the area
of patent law. As a result, the court's failure to address these
issues only perpetuates the existing tension over the balance
between the protection of inventors and innovation with the
protection of the public from harmful patent issuances.
This article will argue that the court's technical resolution of the
case, on subject matter grounds only, could have fittingly
integrated a discussion on the appropriate weight to give policy
and societal concerns to invalidate a harmful patent. In particular,
in the court's application of the "products of nature" exception, the
court could have reconciled Plaintiffs' policy concerns within the
context of the fundamental policy principles at the core of the
"products of nature" exception, effectively giving weight to
Plaintiffs' arguments and still invalidating the BRCA1 and
BRCA2 patents on § 101 grounds.
Section II of this note will first go through the legal basis for
patenting a gene. This will be followed by an account of the
patents that Myriad obtained on the BRCAl and BRCA2 genes
and the value of having identified these genes to the medical
community's effort to make early detections of cancer in women
and men. Section III discusses the subject case of this note,
Association for Molecular Pathology v. USPTO, explaining the
grounds by which the court invalidated Myriad's two patents and
focusing on the court's reasoning that strictly adhered to patent
invalidation on § 101 grounds. Section IV analyzes the subject
case, arguing that the court's invalidation of the patents on § 101
grounds needlessly avoided discussion of Plaintiffs' arguments
based on policy grounds and presenting a method by which the
court could have addressed the societal harms at issue in the
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subject case.
II. BACKGROUND

A. Breast Cancer and the BRCA 1 and BRCA2 Genes
Breast cancer is the most frequently diagnosed cancer
worldwide and is the leading type of fatal cancer in British women
and the second leading type of fatal cancer in American women.2 2
The average American woman whose genes lack an inherited
breast cancer abnormality like a BRCAl/2 mutation has about a
12% risk of developing breast cancer over a 90-year life span.2 3
The average American woman with an inherited mutation in
BRCAl or BRCA2 has a 60% chance of developing breast cancer,
making her about five times more likely to develop breast cancer
than a woman without such a mutation. 24 Breast cancers arising
from mutations in a person's BRCA1 and BRCA2 genes account
for between 5% and 10% of all breast cancers, or between 20,000
and 40,000 cases annually. 25 The remaining 90-95% of cases are
classified as sporadic cancer cases, or cases not due to hereditary
causes. 2 6 Among women with a familial history of breast cancer,
80-90% of cases are the result of DNA mutations in the BRCAl
and BRCA2 genes.
Women with BRCAl/2 abnormalities are also at an increased
22. Ass'nfor MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *49.
23. BreastCancer.org, Genetics,
http://www.breastcancer.org/risk/factors/
genetics.jsp (last visited Feb. 14, 2011).
24. See National Cancer Institute, BRCAl and BRCA2: Cancer Risk and
Genetic Testing, http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA (last
visited Feb. 14, 2011). The names BRCAl and BRCA2 stand for BReast
CAncer susceptibility gene I and BReast CAncer susceptibility gene 2,
respectively. Id. BRCAl and BRCA2 genes are found in everyone and their
mutations are associated with hereditary, or genetically inherited, forms of
breast and ovarian cancer. Id. BRCAl and BRCA2 are believed to be tumor
suppressor genes; when they function normally, or without mutation, they
suppress the growth of cancerous cells. Id.
25. Cook-Deegan, supra note 13, at S19.
26. Duncan, supra note 12.
27. Id

https://via.library.depaul.edu/jatip/vol21/iss2/7

6

Eli: When Myriad Genetics Prohibited a Myriad of Options: Association

2011]

]MYRIAD GENETICS

363

risk of developing ovarian cancer. 28 The lifetime risk is about 55%
for women with BRCAl mutations and about 25% for women
with BRCA2 mutations. 29 By comparison, about 1.8% of women
without an inherited BRCAI or BRCA2 abnormality get ovarian

cancer. 30
The risk for certain other cancers may also be higher in
individuals with BRCAl or BRCA2 mutations.3 ' For instance,
men who inherit abnormal BRCAl or BRCA2 genes have an
increased risk of approximately 6% in developing male breast
cancer. 32 That is about 80 times greater than the lifetime risk for
men without BRCAl or BRCA2 mutations. Men with mutated
BRCAl or BRCA2 genes may also be three to seven times more
likely than men without the mutation to develop prostate cancer.34
BRCAI and BRCA2 mutations occur at a frequency of about 1
in 300-500 in the general population. The risk of inheriting one
of these mutations is much higher in some ethnic groups.36 For
example, certain families in the Netherlands, Iceland, and Sweden
have a higher frequency of BRCA 1/2 mutations."
The United States Preventive Services Task Force" recommends
that women with family histories suggestive of BRCAl or BRCA2
mutations seek appropriate genetic counseling from trained health

28. Breastcancer.org, supra note 23.
29. Id.

30. Id.
31. Id.
32. Id.
33. Id.
34. Breastcancer.org, supra note 23.
35. Id.
36. Cook-Deegan, supra note 13, at S20.
37. Id.
38. The United States Preventive Services Task Force is the independent
panel convened under Agency for Healthcare Research and Quality. The panel
consists of private-sector experts in prevention and primary care medicine
whose members assess scientific evidence to determine the effectiveness of a
broad range of clinical preventive services, including screening, counseling, and
preventive medications. See U.S. Preventive Services Task Force: About the
USPSTF, http://www.uspreventiveservicestaskforce.org/intro.htm (last visited
Feb. 14, 2010).
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care providers." For those who test positive for a mutation, there
are cost-effective approaches for cancer prevention including
screening and surgery, all of which result in gains in both life
expectancy and quality adjusted life years relative to watchful
waiting. 40 For high-risk patients who test negative, there may be
reduced anxiety about the future risks of breast or ovarian cancer.4'
B. Myriad and its Exclusive Licenses
Myriad has established itself as a market leader in gene
discovery and diagnostics by helping to discover and patent the
first genes to be associated with susceptibility for hereditary breast
and ovarian cancer, the BRCAl and BRCA2 genes.4 2 Although
National Institute of Health (NIH) 43 investigators are listed as coinventors on some of the BRCA1/2 patents, NIH assigned
administration of these patents to the University of Utah.44 Myriad
formerly co-owned some of the patents in the lawsuit.45 The
University of Utah subsequently granted exclusive licenses to
Myriad to all the patents involved in the lawsuit, licenses that
Myriad still exclusively held leading up to the lawsuit.46 Having a
USPTO-issued patent on a human gene sequence necessarily
means that the patent holders own the exclusive rights to that
genetic sequence, its usage, and its chemical composition.4 7
39. Cook-Deegan, supra note 13, at S24.
40. Id. at S26.
4 1. Id.
42. Bryn Williams-Jones, History of a Gene Patent: Tracing the
Development and Application of Commercial BRCA Testing, 10 HEALTH L.J.
123, 129 (2002).
43. The National Institutes of Health (NIH), a part of the U.S. Department of
Health and Human Services, is the nation's medical research agency. NIH is the
largest source of funding for medical research in the world, funding thousands
of scientists in universities and research institutions in every state across
America and around the globe. See NIH - About NIH, http://www.nih.gov/
about/index.html (last visited Feb. 14, 2011).
44. Cook-Deegan, supranote 13, at S20.
45. Ass'nfor MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *17.
46. Cook-Deegan, supranote 13, at S20.
47. See 35 U.S.C. § 154(a)(1) (2006). ("Every patent shall contain a short
title of the invention and a grant to the patentee, his heirs or assigns, of the right
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Therefore, gene patent holders such as Myriad had a right to
prevent anyone from studying, testing, or even examining a gene
as this would amount to an infringing use of the genetic sequence.
Myriad's rights effectively prevented anyone else from legally
developing a separate and independent BRCAl/2 screening test in
the United States.4 8
The presence of BRCAl/2 mutations is a definitive factor in the
clinical care for preventing breast, ovarian, and prostate cancer,
particularly for patients deciding whether to undergo any
prophylactic surgeries or more frequent cancer screenings.4 9
Myriad Genetics had sole control of the relevant patents for
BRCA1/2 and was the sole provider of BRCAl/2 genetic testing,
offering a test called BRACAnalysis to screen for mutations in
both genes."o Myriad's Comprehensive BRACAnalysis Test' was
available to patients and clinicians at a cost of over $3000 per test.
Prior to the litigation, 90% of the tests Myriad performed were
covered by insurance for over 90% of the test costs. 52
C. Statutory Subject Matter and the Theories Behind the Products
ofNature Exception
The objective of patent protection, as granted in the Constitution
under Article 1, Section 8 (the "IP Clause"), has long been to
"promote the progress of Science and Useful Arts, by securing for
to exclude others from making, using, offering for sale, or selling the invention
throughout the United States or importing the invention into the United States,
and, if the invention is a process, of the right to exclude others from using,
offering for sale or selling throughout the United States, or importing into the
United States, products made by that process, referring to the specification for
the particulars thereof.").
48. Id.
49. Cook-Deegan, supra note 13, at S24. Surgeries include prophylactic
mastectomy, prophylactic salpingo-oophorectomy, or tubal ligation. Id. at S26.
50. "BRACAnalysis is a genetic test for hereditary breast and ovarian cancer,
based on full DNA sequencing of the BRCAl and BRCA2 genes to identify
deleterious mutations." Williams-Jones, supra note 42, at 133.
51. The Comprehensice BRACAnalysis Test sequences the entire gene,
instead of particular regions of the gene, looking for mutations. See id.
52. Ass'n for Molecular Pathology v. USPTO, No. 09 Civ. 4515 (RWS),
2010 U.S. Dist. LEXIS 35418, at *60 (S.D.N.Y. April 2, 2010).
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limited times to authors and inventors the exclusive right to their
respective writings and discoveries."53 The issuance of a patent
promotes the progress of science by offering inventors exclusive
rights for a limited period as an incentive for their inventiveness
and research efforts. 54 Additionally, society benefits because
inventors disclose their inventions in order to be granted a patent,
fostering scientific and technical openness instead of
confidentiality and secrecy.
Inventions are patentable if they meet the requirements of 35
U.S.C. § 101 that provides, "[w]hoever invents or discovers any
new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof, may obtain a
patent therefore, subject to the conditions and requirements of this
title."56 In evaluating whether a claimed method is patentable
subject matter under § 101, a patent examiner for the USPTO can
analyze the invention under the "machine-or-transformation test."5
Under the machine-or-transformation test, a claimed process can
be patent-eligible under § 101 if: (1) it is tied to a particular
machine or apparatus, or (2) it transforms a particular article into a

53. U.S. CONST., art. 1, § 8, cl. 8.
54. See Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980) (noting that
patent rights encourage ingenuity). Patents provide more than recognition for an
inventor's work; patents serve as a guarantee to scientists and inventors that
their financial investments and scientific findings will be protected. Mark A.
Chavez, Gene Patenting: Do the Ends Justify the Means?, 7 COMP. L. REV. &
TECH J. 255, 255 (2003). Scientists and investors are rewarded this guarantee in
exchange for the expectation that they will advance their innovative research.
Id.
55. Jorge A. Goldstein, Human Gene Patents, 77 ACAD. MED. 1315, 1315
(2002) (citing 35 U.S.C. § 112 (2006)). A valid patent requires a full description
of the invention in the form of a disclosure that assures the invention does not
remain hidden for too long. Id. at 1327.

56. 35 U.S.C. § 101 (2006).
57. See Gottschalk v. Benson, 409 U.S. 63, 70 (1972) ("A process is a mode
of treatment of certain materials to produce a given result. It is an act, or a
series of acts, performed upon the subject-matter to be transformed and reduced
to a different state or thing.").
58. Bilski v. Kappos, 545 F. 3d 943 (Fed. Cir. 2008), af'd, 130 S. Ct. 3218
(2010).
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different state or thing.59
However, the "machine-ortransformation test" is not the only means to determine whether a
process is patent eligible.'
The process must also not be an
abstract idea.'
Other limitations on the scope of patentability also exist. One
limitation is that a patent must serve the public good.62 As such, an
inventor will not be issued a patent for an invention that will harm
the public,63 or for an invention that is of no use to the public.' A
second limitation prevents particular subject matters that are
already available to the public from coming under patent
protection for a specified inventor." Generally, this limitation
operates by requiring that the subject matter of the patent be
novel 66 and nonobvious. 67 This second category of limitations
encompasses the judicially created "products of nature" exception
to patentable subject matter." The determination of patentability
creates a threshold inquiry that precedes the inquiries into novelty,
nonobviousness, and even utility.69
59. Ass'n for Molecular Pathology v. USPTO, No. 09 Civ. 4515 (RWS),
2010 U.S. Dist. LEXIS 35418, at *148 (S.D.N.Y. April 2, 2010).
60. Bilski, 130 S. Ct. at 3227.
61. Id.; Benson, 409 U.S. at 64-67.
62. Brenner v. Manson, 383 U.S. 519, 528-29 (1966).
63. See id. (stating that absence of detriment does not warrant patent
protection).
64. Mere absence of "detriment" is insufficient to warrant patent protection;
there must be a credible utility put forward. Id. at 531-32. The proffered utility
cannot be one of pure research. Id. In Brenner, the Court held that even if the
steroid produced could be shown to have a tumor-inhibiting effect in mice, it
would not be patentable unless that effect could be linked to a utility for human
beings. Id.
65. See 35 U.S.C §§ 102-103 (2006) (prohibiting patents for inventions that
are, among other things, known, already in use, described in printed
publications, appropriated from another person, or identical to another patent).
66. Id. § 102.
67. Id. § 103.
68. Ass'n for Molecular Pathology v. USPTO, No. 09 Civ. 4515 (RWS),
2010 U.S. Dist. LEXIS 35418, at *109 (S.D.N.Y. April 2, 2010) (citing
Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980)).
69. See Chakrabarty, 477 U.S. at 307 ("This case does not involve the other
'conditions and requirements' of the patent laws, such as novelty and
nonobviousness." (quoting 35 U.S.C. §§ 102-103)).
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The "products of nature" exception recognizes three categories
of subject matter that fall outside the scope of § 101 as not
patentable and includes laws of nature, physical phenomena, and
abstract ideas." "Products of nature" do not constitute patentable
subject matter unless the subject matter undergoes a change that
results in the creation of a fundamentally new product.7 ' This
change, or transformation, must somehow alter the natural
properties of a material so that "a new and different article"
emerges that has "a distinctive name, character, or use."72 One
cannot obtain a patent, and the corresponding exclusive right to of
its use, to a natural occurrence and its beneficial properties.
The justification for denying the patentability of a product of
nature is a complex debate that involves public policy, economic
interests, and even religious understandings of nature and man's
limited role in its creations. 74 Boiled down to common parlance,
chemical elements are naturally occurring,7 and their properties
70. Chakrabarty,477 U.S. 308, 309. "Thus, a new mineral discovered in the
earth or a new plant found in the wild is not patentable subject matter.... Such
discoveries are 'manifestations of . . . nature, free to all men and reserved

exclusively to none."' Id.
71. Ass'n for MolecularPathology,2010 U.S. Dist. LEXIS 35418, at *115.
72. Id. (quoting American Fruit Growers, Inc. v. Brogdex Co., 283 U.S. 1,
11 (1931) (holding that an invention impregnating the rind of fruit with borax to
make the fruit resistant to blue mold decay was not a the manufacture of a new
and different article)).
73. Chakrabarty,447 U.S. at 309.
74. See Chavez, supra note 54, at 257. Laws of nature, even when
discovered for the first time, have existed throughout time and define the
relationship of man to his environment; as a consequence, these laws of nature
cannot to be the subject of exclusive rights to any one person and fall out of the
scope of § 101. In re Meyer, 688 F.2d 789, 795 (C.C.P.A. 1982); see also Funk
Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131-32 (The qualities of a
work of nature, "like the heat of the sun, electricity, or the qualities of metals,
are part of the storehouse of knowledge for all men. They are manifestations of
laws of nature, free to all men and reserved exclusively to none. He who
discovers a hitherto unknown phenomenon of nature has no claim to a
monopoly of it which the law recognizes. If there is to be invention from such a
discovery, it must come from the application of the law of nature to a new and
useful end."). Therefore, the USPTO cannot issue patents for the discovery of
the phenomena of nature. Chavez, supra note 54, at 257.
75. See Gen. Elec. Co. v. De Forest Radio Co., 28 F.2d 641, 648 (3d Cir.
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are determined by nature alone.76 Thus, patent law prohibits any
person from commercially controlling these naturally occurring
bounties of nature. Additionally, the purification of a natural
compound is insufficient to render a product of nature patentable
unless the purified product possesses "markedly different
characteristics" in order to satisfy the statutory requirements of §
101."
D. Patent Law and Genomics
In 1980, the United States Supreme Court held in Diamond v.
Chakrabarty that a living, genetically altered microorganism
constituted patentable subject matter."
Such a modified
microorganism was not a product of nature and fell within the
broadly defined concepts of manufacture and composition of
matter.79 The conclusion that a living organism could constitute
patentable subject matter opened the door for the potential
issuance of patents on biological organisms and genes.o In
December 1980, less than a year after the Supreme Court decided
Chakrabarty,the USPTO granted a patent on a recombinant DNA
method."
In 1982, the USPTO granted the University of
1928) (holding that the chemical element tungsten is nonpatentable subject
matter).
76. See, id. at 642 ("If it is a natural thing then clearly, even if [the inventor]
was the first to uncover it and bring it into view, he cannot have a patent for it
because a patent cannot be awarded for a discovery or for a product of nature, or
for a chemical element." (citing U.S. Indus. Chem. Co. v. Theroz Co., 25 F.2d
387, 391-92 (4th Cir. 1928))).
77. Ass'n for Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *132;
The American Wood-Paper Co. v. The Fiber DisintegratingCo., 90 U.S. 566
(1874) (holding that a patent claim for refined cellulose, consisting of purified
pulp derived from wood and vegetable, was not patentable because it was "an
extract obtained from the decomposition or disintegration of material
substance").
78. Diamond v. Chakrabarty,447 U.S. 303, 310 (1980).
79. Id.
80. See Melissa L. Sturges, Who Should Hold Property Rights to the Human
Genome? An Application of the Common Heritage of Humankind" 13 AM. U.
INT'L L. REv 219 (1997).

81. "The

term

recombinant DNA
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California a patent on the gene for insulin.82 The allowance of the
patents on recombinant DNA methods and insulin in the 1980s
was a significant and controversial step in patent law and
biological research."
The work done through the Human Genome Project from 1990
to 2003, a collaborative research project aimed at sequencing the
entire code of human genetic material,84 resulted in the exponential
growth rate of scientific interest and understanding of human
cellular DNA." By 2000, there were more than 25,000 DNAbased patents granted worldwide.86 Researchers for the 2008
Congressional Research Service (CRS) Report estimated that in
2005, United States patents had claimed 20% of human genes.8 7
By the end of 2007, the CRS reported that more than 49,000
patents related to genes, including method of use, had been
issued." The major funding source for biomedical research,
including human genetics, is the National Institutes of Health
(NIH).89
recombining-of two pieces of DNA from different sources, such as from two
different organisms." BIOTECHNOLOGY INDUSTRY ORGANIZATION, GUIDE TO
BIOTECHNOLOGY 2008 (2008), supra note 5, at 18. "Recombinant DNA Artificial DNA made by splicing DNA strands from different organisms. It is
used for many purposes, such as replicating DNA for research, producing
important proteins, and devising gene therapies." Robert Cook-Deegan, From
Birth to Death and Bench to Clinic: The Hastings Center Bioethics Briefing
Book for Journalists, Policymakers, and Campaigns, 70 (Mary Crowley ed.,
Garrison, NY: The Hastings Center, 2008). The patent "laid the groundwork for
using cells to produce useful proteins and tuming them into valuable drugs." Id.
82. U.S. Patent No. 4,431,740 (filed June 8, 1982).
83. Robert Cook-Deegan, From Birth to Death and Bench to Clinic: The
Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and
Campaigns, 70 (Mary Crowley ed., Garrison, NY: The Hastings Center, 2008).
84. Eileen M. Kane, Splitting the Gene: DNA Patents and the Genetic Code,
71 TENN. L. REV. 707, 710 (2004).
85. Ass'nfor Molecular Pathology, 2010 U.S. Dist. LEXIS at *27-28.
86. Williams-Jones, supra note 42, at 126.
87. Wendy H. Schacht, Cong. Research Serv. RS22516, Gene Patents: A
Brief Overview of Intellectual Property Issues, at CRS-2 (2008) (citing Kyle
Jensen and Fiona Murray, "Intellectual Property Landscape and the Human
Genome," Science, Oct. 14, 2005, 239-240).
8 8. Id.
89. David H. Ledbetter, Gene Patenting and licensing: the Role ofAcademic
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The practice of granting patents directed to biological material,
including genetic material and living organisms, has been one of
the "two most controversial areas on patentable subject matter, the
other being mathematical, computer and business related products
and processes.""o Though the Supreme Court has never directly
addressed the question of whether isolated DNA constitutes
patentable subject matter, in 1991, the Federal Circuit held that
"purified and isolated" gene sequences are different from those
occurring in nature."
The court in Amgen, Inc. v. Chughai
Pharmaceuticals Co., Ltd. found that the ingenuity involved in
isolating the useful portions and removing the extraneous portions
of a gene created a new composition of matter that was sufficiently
different from its naturally occurring counterpart to warrant patent
protection. 92 United States patent law allowed the patenting of
human genes when the full-length complementary DNA sequence
was known, and in some cases where only a partial sequence was
known but information on its biological function was unknown. 93
Proposed legislation to rescind the patentability of human genes
has been introduced in Congress but so far has not passed into

law. 94
The United States Patent and Trademark Office is the
administrative agency authorized to examine and grant patents."
According to the 2001 Utility Guidelines published by the
USPTO, DNA molecules were comparable to other chemical
compounds and were eligible for patents when "isolated from their

Researchersand Advocacy Groups, 10 GENET MED 314, 315 (2008).
90. Chisum, supra note 3, at [7].
91. Amgen, Inc. v. Chugai Pharmaceuticals Co., 927 F.2d 1200, 1204 (Fed.
Cir. 1991), cert. denied, 502 U.S. 856 (validating a patent directed to a "purified
and isolated DNA sequence consisting essentially of a DNA sequence encoding
human erythropoietin").
92. Id.
93. Ledbetter, supra note 89, at 316.
94. Id. The Genomic Research and Accessibility Act, H.R. was introduced
in 2007 to halt future patenting of DNA sequences. On Mar 1, 2007, the bill
was referred to the Subcommittee on Courts, the Internet, and Intellectual
Property. H.R. 977, 110th Cong. (2007) available at http://www.govtrack.us/
congress/bill.xpd?bill=hi 10-977.
95. See United States Patent and Trademark Office, supra note 4.
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natural state and purified or when synthesized in a laboratory from
chemical starting materials."9 6 The USPTO distinguished isolated
DNA from natural DNA, the former being patentable because
significant changes are made.97
By purifying, isolating, or
otherwise altering a naturally occurring product, an invention is
patentable if the product is an altered form." Therefore, one could
not patent a naturally occurring DNA sequence as it existed in the
body, but one could patent a gene or protein that had been isolated
from the body.99
E. Disagreementwith USPTO Policy
Much of the tension surrounding the USPTO's policy of
granting patents directed to isolated DNA arose out of debates
over whether isolated DNA is still a "product of nature."'oo Many
critics argue that if isolated DNA is a "product of nature," then the
USPTO should not grant patents directed at isolated DNA because
a true product of nature cannot be patentable subject matter given
that it "does not constitute a machine, composition of matter, or
manufacture."'o
Another point of contention for critics is that granting patents on
isolated DNA creates a potential for a lack of price competition on
96. See Utility Examination Guidelines, 66 Fed. Reg. 1092, cmt. 2 at 1093
(Jan. 5, 2001) (hereinafter 2001 USPTO Guidelines). The USPTO personnel
and examiners used the guidelines in their review of patent applications for
compliance with the utility requirement of 35 U.S.C. § 101. Id. at 1902.
97. Id. at 1903.
98. Cong. Research Serv., supra note 87, at CRS-2.
99. Id.
100. 2001 USPTO Guidelines, supra note 96. "[A] gene is not a new
composition of matter because it exists in nature, and/or that an inventor who
isolates a gene does not actually invent or discover a patentable composition
because the gene exists in nature." Cmt. 2. Compare with, "An isolated and
purified DNA molecule that has the same sequence as a naturally occurring
gene is eligible for a patent because (1) an excised gene is eligible for a patent
as a composition of matter or as an article of manufacture because that DNA
molecule does not occur in that isolated form in nature, or (2) synthetic DNA
preparations are eligible for patents because their purified states is different
from the naturally occurring compound." Id. at Response 2.
101. Chisum, supra note 3, at [7].
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products controlled by few individuals.' 02 When a genetic testing
company, such as Myriad Genetics, obtains exclusive control to a
DNA sequence, the company consequently has the exclusive
control over the use of the sequence necessary to develop the
screening tests.'0 3 This prevents non-patent holding researchers
from identifying and providing more efficient genetic tests; indeed,
with regard to the Myriad patents, this forced some international
researchers to knowingly and intentionally ignore such patents in
order to conduct independent testing.'" French researchers, for
instance, used the patented genetic sequences and developed
different genetic mutation screening strategies in their testing
laboratories to keep costs down for their patients.' 5 The average
cost per mutation detected using the Myriad approach in America
was five times greater than the most cost-effective approach
common to French laboratories.'0 6 This suggests that regardless of
whether isolated DNA sequences are patentable subject matter, for
the sake of keeping health care costs at their lowest, exclusive
licenses to patents may not be the best idea because the licensees
may not care to develop the least expensive testing methods when
they are the sole and exclusive provider of the genetic test.'0 o
In spite of these concerns, advocates for the USPTO's policy of
granting patents directed to isolated DNA argue that the policy is
necessary for the maintenance of the quid quo pro nature of the
patent system.'o Under the quid quo pro structure, inventors must
publicize a sufficient description of the patented invention so that
others may improve upon it in exchange for a limited period of

102. See Cook-Deegan,supra note 13, at S29.
103. Gina Shaw, supra note 15, at 35.
104. Cook-Deegan, supra note 13, at S28.
105. Id. In general, research restrictions in Europe differ from those in
America; several European countries have explicit research exemptions and
diagnostic use exemptions from patent infringement liability that would cover
clinical research testing. Id.
106. Id.
107. See id
108. Ass'n for Molecular Pathology, 2010 U.S. Dist. LEXIS 35418 at *80.
The right of exclusion is the inventor's "reward for inventions." Kewanee Oil
Co. v. Bicron Corp., 416 U.S. 470, 480 (1974) (citing Universal Oil Co. v.
Globe Co., 322 U.S. 471, 484 (1944)).
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patent exclusivity.109 In exchange, this exclusivity then precludes
competitors from profiting from the inventor's creation and
empowers the inventor to capitalize on his patent."o
In Myriad's case, the mere prospect of obtaining patents on the
BRCAl/2 genes played an essential role in the initial BRCAl/2
researchers successfully securing capital investment for isolating
and sequencing the genes because investors knew that patented
In the
sequences had a potential for significant profits."'
identification of the BRCAl and BRCA2 sequences, the
University of Utah researchers and Myriad needed and
successfully secured private investments."12 In turn, investors
placed heavy expectations on the fact that patent law would protect
their investment."' These concerns and tensions surrounding the
USPTO's gene-patenting policies were some of the major
considerations underlying the following case.
III. SUBJECT OPINION

In Association for Molecular Pathology v. USPTO, the court
invalidated Myriad's BRCAl and BRCA2 patents as not
patentable subject matter under 35 U.S.C. § 101." Citing the
"products of nature" exception, the court found that DNA in its
isolated form alters neither the fundamental property of DNA as
the physical embodiment of biological information nor the
information it encodes."'5 The court also invalidated the method
claims for comparing DNA sequences because the claims were
directed at abstract mental processes and therefore not patentable

109. Ass'n for MolecularPathology, 2010 U.S. Dist. LEXIS 35418 at *80.
110. Id.
S11.Id. at *80-81.

112. 1d. at *81.
113. Id. "Myriad asserts that absent the promise of a period of market
exclusivity provided by patents and the infusion of venture and risk capital
derived therefrom, companies such as Myriad that capitalize on innovation
simply would not be created and their products would not be brought to market
or the clinic." Id. at *82.
114. Id.at*5.
115. Id. at *4-5.
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subject matter under § 101."6

A. Parties

1. Plaintiffs
The Association for Molecular Pathology, the named Plaintiff, is
a not-for-profit scientific society dedicated to the advancement and
practice of clinical molecular laboratory medicine and translational
research based on the applications of genomics and proteomics."'
Additional Plaintiffs were different science laboratory
organizations,"' woman's health advocacy centers,"' individual
physicians and researchers interested in working with BRCA1 and
BRCA2 who were precluded from doing so because of Myriad's
patents,120 and cancer patients or at risk patients in some measure
precluded from obtaining the BRCAl/2 genetic sequencing test

offered exclusively by Myriad.121
116. Id. at *5.
117. Id. at *6-7; see also Association for Molecular Pathology, About AMP,
http://www.amp.org/about/mission vision.cfm (last visited Oct. 9, 2010).
"Genomics is the study of all the genes of a cell, or tissue, at the DNA
(genotype), mRNA (transcriptome), or protein (proteome) levels." UNITED
STATES ENVIRONMENTAL PROTECTION AGENCY,

SCIENCE POLICY COUNCIL:

INTERIM POLICY ON GENOMICS 2, http://epa.gov/osa/spc/pdfs/genomics.pdf.

Proteomics refers to the study of the proteome, a term first used in 1994 to
describe "all the proteins in a cell, tissue, or organism." Clinical Proteomic
Technologies for Cancer, http://proteomics.cancer.gov/about/FAQs.asp#l (last
visited Oct. 9, 2010).
118. Ass'n for Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *7-9.
Plaintiffs include the American College of Medical Genetics, the American
Society for Clinical Pathology, and the College of American Pathologists. Id.
119. Id. at *13-14. Plaintiffs additionally include Breast Cancer Action, a
national organization that provides representation to those individuals affected
by breast cancer, and Boston Women's Health Book Collective. Id
120. Id. at *9-13. Plaintiffs included Haig Kazazian, M.D., Anupa Ganguly,
Wendy Chung, M.D., Harry Ostrer, M.D., David Ledbetter, Ph.D., Stephen T.
Warren, Ph.D, Ellen Matloff, M.S., and Elsa W. Reich, M.S. Id.
121. Id. at *14-16. Plaintiffs include breast cancer patient Lisbeth Ceriani,
cancer patient Runi Limary, breast cancer patients Genae Girard and Patrice
Fortune, ovarian cancer patient Vicky Thomason, and at-risk breast cancer
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Amici for the Plaintiffs included not-for-profit organizations
representing physicians and medical students throughout the
United States, not-for-profit organizations dedicated to advancing
the treatment of a variety of genetic diseases, not-for-profit
organizations seeking to improve the health of women, and notfor-profit organizations dedicated to assisting the public and policy
makers in understanding how technology affects society.'22
2. Defendants
Defendant members were neither as numerous nor as diverse as
Plaintiffs. Defendant USPTO was named because it was the
government organization that issued the patents to Myriad
Genetics containing the claims-in-suit.'23 Myriad was the former
co-owner of several of the patents-in-suit and the exclusive
licensee of all the patents-in-suit, solely providing the full
sequencing of BRCAl and BRCA2 genes in the United States on a
commercial basis.124
Defendants additionally included the
patient Kathleen Raker. Id. Ceriani was insured through MassHealth, a
Medicaid insurance program for low-income people that Myriad does not
accept, and was unable to afford the out-of-pocket costs for Myriad's genetic
test. Id. at * 14. Limary received an inconclusive test result through Myriad and
cannot pursue alternative testing options. Id. at *15. After testing positive,
Girard could not obtain a second opinion because only Myriad could provide the
full BRCAl/2 sequencing in America. Id. Fortune was unable to pay the full
out-of-pocket cost for the BRCAl/2 genetic testing and Myriad did not accept
her insurance. Id. Thomason and Raker were unable to afford the extra cost for
the BRCA1/2 genetic testing. Id. at *16.
122. Id. at *17-20. Amici include the American Medical Association,
American Society of Human Genetics, American College of Obstetricians and
Gynecologists, American College of Embryology, The Medical Society of the
State of New York, March of Dimes Foundation, Canavan Foundation, Claire
Altman Heine Foundation, Breast Cancer Coalition, Massachusetts Breast
Cancer Coalition, National Organization for Rare Disorders, National TaySachs & Allied Disease Association, National Women's Health Network, Asian
Communities for Reproductive Justice, Center for Genetics and Society,
Generations Ahead, Pro-Choice Alliance for Responsible Research, The
International Center for Technology Assessment, Indigenous People Council on
Biocolonialism, Greenpeace, Inc., and Council for Responsible Genetics. Id
123. Id. at * 16-17.
124. Ass'n for Molecular Pathology,2010 U.S. Dist. LEXIS 35418, at *17.
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University of Utah Research Foundation.125
Amici for Defendants included health advocacy and diagnostic
28
companies,12 patent legal professionals,' 27 and law professors.1
B. Myriad's Notices on the Infringement and the Patents'
Enforcement
Myriad actively enforced its patent claims against researchers
and physicians, in several instances sending cease and desist letters
to known scientists and Plaintiff party members to terminate all
their infringing BRCAl/2 research or offering limited
collaborative licenses.129 As a means to enforce its patent claims,
Myriad offered Plaintiff Dr. Haig Kazazian, a physician and
human genetics researcher, a limited collaborative license covering
the screening for only a fraction of the known mutations for which
tests exist.'
Dr. Kazazian's laboratories performed BRCA1/2
analysis for research members of the Cancer Genetics Network
Project (CGNP), sponsored by the National Cancer Institute."' Dr.
Kazazian did not accept the offer for limited screening, and
Myriad eventually sent cease and desist letters to Dr. Kazazian and
the University of Pennsylvania, notifying each that their actions in
125. Id. The University of Utah Research Foundation is an owner or part
owner of each of the patents-in-suit. Id.
126. Id. at *21-24. Amici include Genetic Alliance, Rosetta Genomics, Inc.,
BayBio, Celera Corporations, The Coalition for 21st Century Medicine,
Genomic Health, Inc., Qiagen, N.V., Target Discovery, Inc., XDx, Inc. Id.
127. Id. at *21, 25. Amici include the Boston Patent Law Association and
Kevin E. Noonan, Ph.D., J.D.
128. Id. at *24. Amici include Kenneth Chahine, Ph.D.
129. Id. at *61-64.
130. Ass'nfor Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *6162. Dr. Kazazian is the Seymour Gray Professor of Molecular Medicine in
Genetics in the Department of Genetics at the University of Pennsylvania
School of Medicine. Id. at *9. He is also the previous chair of the Department.
Id.
131. Id. at *61. The Cancer Genetics Network is a research resource for
investigators conducting research on the genetic basis of human cancer
susceptibility, with over 435,000 individual family members currently enrolled.
See National Cancer Institute, Epiodemiology and Genetics Research,
http://epi.grants.cancer.gov/CGN/ (last visited Jan. 29, 2011).
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the absence of a license constituted infringement.'32 As a result,
Dr. Kazazian and his laboratories terminated all BRCAl/2
screening both for research with other scientists and as part of its
clinical practice.'13
Plaintiff Dr. Harry Ostrer, also a physician and researcher on the
genetic basis of development and disease, similarly declined to
enter into a limited license agreement in May 1998 with Myriad,
noting that it "was too narrow to allow him to perform any
meaningful BRCAl/2 testing."'34
Myriad likewise notified Dr. Barbara Weber, a principal
investigator on the CGNP sponsored by the National Cancer
Institute, in September 1998 that its patents impacted her research
contributions to the CGNP, consequently terminating the
BRCAI/2 analysis by Dr. Kazazian on Dr. Weber's research
samples.' In September 1999, Myriad also requested that another
CGNP member, Georgetown University, cease sending genetic
samples to Dr. Kazazian for BRCA1/2 analysis.'36
In December 2000, Myriad sent a cease and desist letter to the
Yale DNA Diagnostic Lab concerning its BRCAl/2 genetic
testing, to which the lab obliged.' When the laboratory director
sought permission from Myriad to conduct screening specifically
for genetic mutations in the BRCAl/2 genes for which Myriad was
not currently screening, Myriad denied her request.'38

132. Ass'nfor Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *6162.
133. Id. at *62-63.
134. Id. at *63. "Dr. Ostrer is a Professor of Pediatrics, Pathology and
Medicine and Director of the Human Genetics Program in the Department of
Pediatrics at New York University School of Medicine." Id. at *10.
135. Id. at *63-64.
136. Id. at *64.
Georgetown University was another cancer center
participating in the CGNP. Id.
13 7. Id.
138. Ass'n for Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *64.
These mutations, not screened by Myriad, included mutations caused by large
rearrangements. Id.
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C. The Complaint
Plaintiffs filed a complaint in 2009 against the USPTO and
Myriad, alleging violations of 35 U.S.C. § 101 of the patent
statute, Article 1, Section 8, (the "IP Clause") of the United States
Constitution, and the First and Fourteenth Amendments to the
United States Constitution.'" First, Plaintiffs alleged that "human
genes are products of nature, laws of nature and/or natural
phenomena, and abstract ideas or basic human knowledge or
thought" and therefore the issued patents were in violation of both
§ 101 of the patent statute and the IP Clause. 40 Second, Plaintiffs
alleged that "[a]ll the challenged claims represent[ed] patents on
abstract ideas or basic human knowledge and/or thought and as
such are unconstitutional under the First and Fourteenth
Amendments." 4 '
In prior proceedings on November 1, 2009, Plaintiffs withstood
Defendants' motion to dismiss the complaint.'4 2 Plaintiffs' suit
challenged the patent claims "directed to (1) isolated DNA
containing all or portions of the BRCA1 and BRCA2 gene
sequence and (2) methods of 'comparing' or 'analyzing' BRCAl
and BRCA2 gene sequences to identify the presence of mutations
correlating with a predisposition to breast or ovarian cancer."l43
Plaintiffs asserted that Myriad's patents and its monopolizing
control of all BRCA1/2 testing hindered the ability of patients to
obtain breast cancer genetic testing and precluded any research to

102, 103. Plaintiffs' statutory claim
139. Compl. supra note 9, at 29,
brought under the Patent Act alleged that Myriad's patents were invalid for
failing to meet the statutory requirements for patentable subject matter for the
proper granting of a patent. Id. at 19, 152.
140. Id. at 29, 1102.
141. Id. at 29, 103. The First Amendment states that "Congress shall make
no law respecting an establishment of religion, or prohibiting the free exercise
thereof; or abridging the freedom of speech, or of the press . . .". U.S. CONST.

amend I. The Due Process Clause of the Fourteenth Amendment prohibits state
and local governments from depriving "any person of life, liberty, or property
without due process of the law." U.S. CONST. amend XIV.
142. Ass'n for MolecularPathology,2010 U.S. Dist. LEXIS 35418, at *6.
143. Id. at *3.
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develop improved BRCAI/2 genetic testing.'" Plaintiffs further
asserted that other labs existed with the ability to offer not only
more comprehensive testing than Myriad but also newer testing
methods for improved testing quality, accuracy, and efficiency.'45
Plaintiffs' repeated concern was that the need for the BRCAl/2
screening test was great, yet the ability for a patient to get a second
confirmatory test done through another lab, the "second-opinion"
patients naturally seek for numerous diagnoses, was nonexistent as
a result of the patents-in-suit.'46
Plaintiffs' action against Myriad targeted fifteen claims
contained in seven patents issued to Myriad by the USPTO.'47 The
claims-in-suit were either composition claims or method claims.'48
The composition claims reached isolated BRCA1/2 DNA obtained
from any human being.'49 The method claims were directed to the
process of determining whether an individual has inherited an
altered BRCAl or BRCA2 gene by comparing the individual's
BRCAl and BRCA2 gene sequences with the wild type, or unmutated, BRCAl and BRCA2 gene sequences.'
Plaintiffs cited studies examining the lag time between the
issuance of a patent claiming a gene sequence and the subsequent
publication of papers on that gene sequence as a negative impact
on knowledge of that sequence, noting that in the case of BRCAl
and BRCA2, Myriad's patents negatively impacted public
awareness of the genes' identification and role in breast and

144. Id. at *65.
145. Id. at *66.
146. Id. at *69-70.
147. These claims and patents include: claims 1, 2, 5, 6, 7, and 20 of U.S.
patent 5,747,282; claims 1, 6, and 7 of U.S. patent 5,837,492; claim I of U.S.
patent 5,693,473; claim I of U.S. patent 5,709,999; claim 1 of U.S. patent
5,710,001; claim I of U.S. patent 5,753,441; and claims 1 and 2 of U.S. patent
6,033,857. Id. at *83.
148. Ass'nfor MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *84.
149. The composition claims include: claims 1, 2, 5, 6, and 7 of U.S. patent
5,747,282; claim I of U.S. patent 5,693,473; claims 1, 6, and 7 of U.S. patent
5,837,492. Id. at *86-87.
150. The method claims include: claim 1 of U.S. patent 5,709,999; claim I of
U.S. patent 5,710,001; claim I of U.S. patent 5,753,441; claim 20 of U.S. patent
5,747,282; and claims 1 and 2 of U.S. patent 6,033,857. Id. at *87-89.
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ovarian cancers by 5-10%.'
Myriad's cease and desist letters successfully precluded labs
from performing BRCA1/2 genetic testing and researching
alternative tests for screening BRCA1/2 mutations. 5 2 The gene
patents may even have impeded the development of genetic testing
for other diseases; the scope of BRCAl/2 mutations was not yet
confirmed as limited only to breast and ovarian cancer in women
and breast and prostate cancer for men.'53 Proponents for the
invalidation of these patents argued that as long as these patents on
gene sequences remained, no one would be able to study these
genes for other disease predisposition.'54
While Myriad and its collaborators expended considerable effort
and ingenuity to isolate the BRCA1/2 genes, they utilized widely
understood approaches of fairly uniform isolation processes
throughout the science and genetic research community.'
Plaintiffs alleged that "a number of researchers, clinicians and
molecular pathologists have the personnel, equipment, and
expertise to sequence and analyze genes, including the BRCA1
and BRCA2 genes, at a lower cost than Myriad's testing."'5 6
D. The Court'sHolding andAnalysis

1. Defining "Work ofNature" and "IsolatedDNA"
After a
sequencing
Myriad or
information

lengthy and technical description of the DNA
process, the court held that the sequencing process
any other geneticists employed did not alter the
content of the original, native DNA sequence.' The

151. Id. at *73. These are the conclusions of Dr. Fiona Murray, a researcher
who studied the impact of gene patenting on scientific research and
commercialization.
152. Id. at *75.
153. Sarah Zielinski, BRCAI Discovery Led to Patent Debate, Genetic
Screening, 96 J. NAT'L CANCER INST. 986 (2004).

154.
155.
156.
157.

Ass'nfor Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *78.
Id. at *55.
Id. at *60.
Id. at *25-48.
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court analogized the process of sequencing to examining material
though a microscope, noting that both make visible something that
exists in nature but is too small to be seen otherwise.'
Genetic
mutations associated with a particular condition, like a BRCAl or
BRCA2 mutation and its association to breast and ovarian cancer,
are caused by nature.'59 The court then stated that nature dictated
the significance of any person's genetic sequence, whether wild
type or mutated, and its relationship to any disease.'60 Thus,
isolated DNA is just a magnification of a person's genetic
sequence.

16'

The court, in resolving the meaning of "isolated DNA,"
accepted Myriad's definition from the patent specifications that
isolated DNA as used in the patent referred to "a segment of DNA
nucleotide existing separate from other cellular components
normally associated with native DNA, including proteins and other
DNA sequences comprising the remainder of the genome, and
includes both DNA originating from a cell as well as DNA
synthesized through chemical or heterologous biological

means."l 62
2. Composition Claims and Method Claims: Not Patentable
Subject Matter
In considering whether the patents-in-suit complied with § 101,
the court analyzed (1) whether the claimed invention possessed
utility; and (2) whether the claimed invention constituted statutory
subject matter 6 1 or whether the claimed invention instead fell
within the judicially created "products of nature" exception to

158. Id. at *45.
159. Id. at *45-46.
160. Ass'nfor Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *4546.
161. Id.
162. Id. at *99.
163. Section 101 provides "Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of matter, or any new and useful
improvement thereof, may obtain a patent therefore, subject to the conditions
and requirements of this title." 35 U.S.C. § 101 (2006).
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patentable subject matter.'6" Because there was no dispute that the
composition and method claims possessed utility, the court's
opinion focused strictly on whether the claimed compositions and
methods constituted patentable subject matter, or, in the
alternative, if they fell within the judicially created "products of
nature" exception, inclusive of laws of nature, physical
phenomena, and abstract ideas.165
The court determined that the composition claims directed to
isolated DNA that contain naturally occurring sequences fell

within the "products of nature" exception to 35 U.S.C. § 101,166
reasoning that isolated DNA does not meet the § 101 requirement
of having a "new or distinctive form, quality, or property" from a
product of nature. 6 1
The court rejected Myriad's argument that isolated DNA
molecules should be treated no differently than other chemical
compounds for patent eligibility."' The court concluded that
because DNA is unique, as evidenced by the double nature of
genes as chemical molecules and physical carriers of
information,' 9 it cannot be confined to its chemical properties and
treated like other objects.'" The differences cited between isolated
DNA claimed in the patents and native DNA found within human
cells were insufficient to "establish the subject matter patentability
of isolated BRCAl/BRCA2 DNA.""'

The court's holding was "driven by the overriding importance of
DNA's nucleotide sequence to both its natural biological function
164. Ass'n for MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *109
(citing Diamond v. Chakrabarty, 477 U.S. 303, 309 (1980)).
165. Id. at *109. The judicially created products of nature exception to
patentable subject matter include "laws of nature, natural phenomena, and
abstract ideas." Chakrabarty,447 U.S. at 309.
166. Ass'n for MolecularPathology,2010 U.S. Dist. LEXIS 35418, at *110.
167. Id. at *114-15 (quoting Am. Fruit Growers v. Brogdex Co., 283 U.S. 1,
11(1931)).
168. Id. at*132-33.
169. Id. at *133-34. As explained by Myriad's expert Dr. Joseph Straus,
genes are multifunctional because they are chemical substances as well as
physical carriers of information whose biological function as a chemical is
determined by this information. Id.
170. Id. at*135-36.
171. Id. at *132.
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as well as the utility associated with DNA in its isolated form."I72
Because of DNA's unique qualities as a "physical embodiment of
information," neither the structural nor the functional differences
argued by Myriad between native BRCA1/2 DNA and the claimed
isolated BRCAl/2 DNA rendered the claimed isolated DNA
"markedly different.""' The court relied on the preservation of
this defining characteristic of DNA in both its native and isolated
forms in finding that the challenged composition claims were
directed to unpatentable products of nature.'7 4
DNA must be isolated and absent of proteins and other
nucleotide sequences through purification for it to be useful for
Myriad's claimed methods."' However, this "purification of
native DNA does not alter its inherent characteristics, the
nucleotide sequence, that is defined by nature and central to both
its biological function within the cell and its utility as a research
tool in the lab."'7 6 The utility of isolated DNA for the various
purposes cited by Myriad did not prove the differences between
native and isolated DNA necessary to establish the subject matter
patentability of what is otherwise a product of nature."' While the
court noted the complexity of Myriad's discovery of the specific
segments of chromosomes 17 and 13 that correlated with breast
and ovarian cancer, it qualified the discovery as the "handiwork of
nature" and "the natural effect of certain mutations in a particular
segment of the human genome.""' The court concluded its
discussion on the composition claims by saying that "[b]ecause the
claimed isolated DNA [was] not markedly different from native
DNA as it exists in nature, it constituted unpatentable subject

matter under 35 U.S.C. § 101."'7
Next, the court next applied the "machine-or-transformation
test" to determine whether the process or method claims were
172.
173.
174.
175.
176.
177.
178.
46.
179.

Ass'nfor MolecularPathology,2010 U.S. Dist. LEXIS 35418, at *136.
Id. at *135-36.
Id. at *136.
Id.
Id.
Id. at *144-45.
Ass'n for MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *145Id. at *147.
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tailored narrowly enough to encompass only a particular
application of a fundamental principle rather than pre-empt the
principle itself.'" Under the machine-or-transformation test, a
claimed process is patent-eligible under § 101 if: (1) it is tied to a
particular machine or apparatus, or (2) it transforms a particular
article into a different state or thing.'"' Under each standard, the
court held that the method claims were invalid.18 2
The court rejected Myriad's argument that the act of "analyzing"
or "comparing" BRCA1/2 gene sequences may fulfill the
requirements
of the machine-or-transformation
test as
transformative steps.'
The language in these method claims,
compared to the plain and ordinary meanings of the terms
"analyzing" and "comparing," established only that the method
claims were directed to the abstract mental process of "analyzing"
or "comparing."' 8 4 While the purpose of the method claim was
perhaps to "detect a germline alteration in a BRCA1 gene," the
method actually claimed was "analyzing a sequence of a BRCA1
gene."' 85
The court also held that the essence of the method claim for
"comparing" the growth rates of cells in the presence or absence of
a possible cancer therapeutic was merely the act of comparing cell
180. Id.
181. Id. at *148 (citing In re Bilski, 545 F.3d 943, 954 (Fed. Cir. 2008),
aff'd, Bilski v. Kappos, 130 S. Ct. 3218 (2010)). "This Court's precedents
establish that the machine-or-transformation test is a useful and important clue,
an investigative tool, for determining whether some claimed inventions are
processes under [35 U.S.C.] § 101. The machine-or-transformation test is not
the sole test for deciding whether an invention is a patent-eligible 'process."'
Bilski, 130 S. Ct. at 3227. Although the Supreme Court in Bilski did rule that
the machine-or-transformation test is not a per se rule for subject matter
patentability on a method claim, it held that the method claims were still not
patentable subject matter because they were abstract. Id. at 3231. If a process
claim does not meet the machine-or-transformation test, it is to be rejected as
not patent eligible unless there is clear indication that it is not an abstract idea.
Id.
182. Ass'n for MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *149,
159.
183. Id. at*151-52.
184. Id. at*153.
185. Id.
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growth rates to determine that the possible therapeutic was
possibly a cancer therapeutic.'" This was not a valid method claim
because it sought to patent a basic scientific principle: "that a
slower rate of cell growth in the presence of a compound indicates
that the compound may be a cancer therapeutic."'" Such datagathering steps do are not transformative and render the claimed
mental process of "comparing" unpatentable under § 101.188
3. Dismissal of all Other Claims Against the USPTO
Because the claims-in-suit were invalidated pursuant to 35
U.S.C. § 101,8" the court applied the doctrine of constitutional
avoidance that precluded it from reaching the constitutional claims
against the USPTO.'9 e The court left the issue of the USPTO's
policy in granting patents on isolated DNA sequences open to the
Federal Circuit or the Supreme Court."' Until then, the court
reasserted the applicability of its ruling to bind the USPTO,
forcing the conformation of its examination policies to void
issuing patents directed to isolated DNA or the comparison or
analysis of DNA sequence.'92
IV. ANALYSIS
Although the Southern District of New York properly
invalidated the BRCAl and BRCA2 patents on statutory grounds,
the court established a sweeping rule that categorically invalidates
all patents on isolated DNA. It did so without providing any
guidance regarding the appropriate weight to give policy and
societal concerns to invalidate a patent. The court's technical
resolution of the case should have instead integrated a discussion
on the appropriate weight to give social policy concerns when
186.
187.
188.
189.
190.
should
191.

Id. at*159.
Id. at *161.
Ass'n for MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *161.
Id. at*164.
Id. at *163. The doctrine of constitutional avoidance states that courts
not reach an unnecessary constitutional question. Id. at * 161.
Id. at *163.

192. Id.
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invalidating a harmful patent. The failure to do so perpetuates the
tension of how to balance the protection of inventors and
innovation versus the protection of the public from oppressively
monopolistic patents.
The opinion certainly adhered to proper precedent in evaluating
the treatment of patentable subject matter and the exceptions for
products existing in nature.'93 However, the court's reliance on the
"products of nature" exception should have also addressed
Plaintiffs' social policy arguments by analogizing them to the
policy arguments at the core of the "products of nature" exception.
Moreover, the court should have addressed the underlying purpose
of the "products of nature" exception: meeting the United States'
Constitutional prerogative "to promote the Progress of Science and
useful Arts."'9 4
The court gave an extensive description of the harms and
individual parties' concerns with patents on isolated DNA
sequences that clearly indicated its awareness of the underlying
concerns surrounding the issuance of patents in this context.
However, the court failed to provide any kind of legal resolution
on these highly important issues. As a result, uncertainty persists
as to how future courts are to effectively address concerns as to
issuances of patents that prove to foster more public harm than
public good. In future cases, where it may be more difficult to
invalidate a patent on technical terms, courts faced with a patent
that clearly serves to stifle research and create prohibitive costs on
society will have little guidance on how to invalidate such a patent
on more policy based grounds. Given the particular facts before it,
the Southern District of New York's approach in deciding this
matter is troubling. Here, the welfare of thousands of cancer
patients was threatened by Myriad's patent protection.'95 It is hard
to fathom a riper time to address these critical issues, particularly

193. See Diamond v. Chakrabarty,447 U.S. 303, 305 (1980).
194. U.S. CONST., art. 1, § 8, cl. 8.
195. The court recognized the consequences of its decision, stating that the
"resolution of the issues presented . . . deeply concerns breast cancer patients,
medical professionals, researchers, caregivers, advocacy groups, existing gene
patent holders and their investors, and those seeking to advance public health."
Ass'nfor Molecular Pathology,2010 U.S. Dist LEXIS, at *3-4.
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when the legislature has failed to assist in the endeavor.
The concerns over the harms of patents are neither new nor
limited to isolated DNA patents and genetic screening,9 and the
court's technical resolution of the matter may not be feasible to
invalidate other patents that prove harmful.17 This case serves as
further evidence that many other issues exist with the legal rights
permitted by the patent system that are in need of legislative or
judicial interference and final resolution.'
A. The Court Missed a Golden Opportunity to Incorporatethe
ReasoningBehind the "ProductsofNature" Exception into Its
Discussion
The Southern District of New York failed to resolve Plaintiffs'
societal concerns by discussing the purpose underlying the
"products of nature" exception. The need to strike a balance in
today's high paced innovative research community "between
protecting inventors and not granting monopolies over procedures
that others would discover by independent, creative application of
general principles" is a pressing matter for the federal courts.'99 As
the United States Supreme Court noted in 2010, in its most recent
196. See Chakrabarty,447 U.S. at 318 (Brennan, J., dissenting) (arguing that
Congress, in exercising its authority under Art. 1, § 8, of the constitution, never
intended that an inventor could secure a monopoly on a living organism, no
matter how the inventor produced or used the organism).
197. The court acknowledged and agreed that there does "exist a sharp
dispute concerning the impact of patents to isolated DNA on genetic research."
Ass'nfor Molecular Pathology, 2010 U.S. Dist LEXIS, at *82. However, the
court went on to acknowledge the impossibility of any "resolution of these
disputes" based on the motions in the suit against Myriad. Id. at *83. To that
end, the court warned that its decision would not bring consolation to many of
the parties' arguments, instead leaving the topic open for future debate and
resolution.
198. See Chakrabarty,447 U.S. at 317 (Burger, J., majority) (noting that the
process of invalidating an entire type of invention from patent protection
"involves the balancing of competing values and interests, which in our
democratic system is the business of elected officials. Whatever their validity,
the contentions now pressed on us should be addressed to the political branches
of the Government, the Congress and the Executive, and not to the courts").
199. Bilski v. Kappos, 130 S. Ct. 3218, 3228 (2010).
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patent law case Bilski v. Kappos, the federal courts' refusal to
"take a position on where that balance ought to be struck" is an
issue that the courts cannot continue to ignore forever.200 In the
meantime, the fundamental justification to protect society from
harmful patents in the creation of the "products of nature"
exception offers an effective and valuable starting point as an
extension of the constitutional prerogative that the IP Clause
creates for finding the balance in patents that do more harm than
good.
1. The "Products ofNature" Exception is Necessary in PatentLaw
The "products of nature" exception, though judicially created, is
not an arbitrary creation or an instance of judicial activism in the
federal courts to impose limitations on the patent system. The
exception instead exists out of necessity to preclude inventors from
denying the public access to something that has always been held
by the public, though only recently discovered or conceptualized,
such as "a new mineral discovered in the earth or a new plant
found in the wild."20 ' However, the exception's repeated use for
over a century has focused mostly on the potential inventions that
are not patentable subject matter because they fall within the
exception.202 Courts' applications of the exception in patent case
opinions to determine patentability are unaccompanied by any
discussion of the reasoning behind the exception or the merits
supporting its continued use.203 Nevertheless, the exception's use
is a reaffirmation of its goal to make certain that discoveries of
purely natural phenomena remain in the public domain. The social
policy concerns weighing against Myriad's patents presented the
perfect opportunity for the court to finally discuss and give weight
to the goals of societal protection that lie at the foundation of the
"products of nature" exception.

200. Id.
201. Diamondv. Chakrabarty,447 U.S. 303, 309 (1980).
202. See id.; Parker v. Flook, 437 U.S. 584, 595 (1978); Gottschalk v.
Benson, 409 U.S. 63, 67 (1972); Funk Bros. Seed Co. v. Kalo Inoculant Co.,
333 U.S. 127, 130 (1948); O'Reilly v. Morse, 56 U.S. 62, 112-21 (1854).
203. See id.
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The purpose of the "products of nature" exception is to place
limitations on the scope of patentable subject matter for inventions
that are contrary to the IP Clause. This, in turn, allows all
members of society the opportunity to freely utilize the "laws of
nature, natural phenomena, and abstract ideas in their own creative
endeavors without fear of being sued for patent infringement."2 04
The most noted iteration of the reasoning for the "products of
nature" exception, as expressed by Supreme Court Justice Stephen
Breyer in his dissent over the dismissal of certiori in Laboratory
CorporationofAmerica Holdings v. Metabolite Laboratories,Inc.,
joined by Justices Stevens and Souter, parallels the reasoning
behind the arguments made against the USPTO practice of
granting patents to isolated DNA:
[T]he justification for the principle does not lie in
any claim that "laws of nature" are obvious, or that
their discovery is easy, or that they are not useful.
To the contrary, research into such matters may be
costly and time-consuming; monetary incentives
may matter; and the fruits of those incentives and
that research may prove of great benefit to the
human race. Rather, the reason for the exclusion is
that sometimes too much patent protection can
impede rather than 'promote the Progress of
Science and useful Arts.' . . . Sometimes their

presence can discourage research by impeding the
free exchange of information, for example by
forcing researchers to avoid the use of potentially
patented ideas, by leading them to conduct costly
and time-consuming searches of existing or pending
patents,
by
requiring
complex
licensing
arrangements, and by raising the cost of using the
patented information, sometimes prohibitively so.205

204. Diamond v. Diehr, 450 U.S. 175, 185 (1981).
205. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124,
126-27 (2006) (Breyer, J., dissenting over the dismissal of certiori) (quoting
U.S. CONST., art. 1, § 8, cl. 8).
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According to Justice Breyer, there are inherent and obvious
dangers that arise when a patent is granted on a purported
invention that is actually a "product of nature." Therefore, the
negative and intolerable consequences of the USPTO's actions of
granting patents on isolated DNA in violation of the "products of
nature" exception were foreseeable in light of Justice Breyer's
previous identification. These foreseeable dangers of patents on
"products of nature" are exemplified in the latter part of the quoted
material from Justice Breyer and reaffirm the understanding that
the exception is one born from necessity because otherwise, these
patents would effectively work against the constitutional reasoning
behind the creation of the American patent system. In this regard,
Plaintiffs' policy arguments warranted a closer inspection by the
court. The case against the validity of Myriad's BRCA1/2 patents
was a golden opportunity for the Southern District of New York to
bring some resolution to Plaintiffs' concerns and guide the
USPTO's future practices.
2. ForeseeableDangers ofPatents on IsolatedDNA Sequences
The exclusion of "products of nature" from patentable subject
matter is a workable reality that has defined the American patent
system that recognizes that certain "manifestations of . .. nature,

[are] free to all men and reserved exclusively to none."26 This
premise is not arbitrary, as legitimate concerns exist to necessitate
such a rule that would protect natural phenomena from removal
from the public domain while maintaining a patent system that
encourages and enables further research.
Continued validity of certain patents directed at isolated DNA,
like the BRCAl and BRCA2 patents, served to impede the "free
exchange of information" because the patent enforcement
"force[d] researchers to avoid the use of potentially patentable
ideas."207 Plaintiffs presented substantial evidence that in the case
of Myriad's patents, enforcement of the patent rights caused great
harm by impeding the progress of necessary scientific research, the
206. Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S 127, 130 (1948).
207. Lab. Corp., 548 U.S. at 126-27 (Breyer, J., dissenting over the dismissal
of certiori).
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availability of patient care, and the development of more efficient
tests. 20' For example, Myriad's patent enforcement forcibly
precluded researchers from developing alternative screening for
the BRCAI and BRCA2 mutations for fear of litigation.209
Alternative screening could potentially be less expensive and also
more accurate than Myriad's BRACAnalysis test. In British
Columbia, Canada, cancer agencies started providing in-house
BRCAl/2 mutation testing in 1995. In 2001, when the B.C.
Ministry of Health Services' efforts were futile in enforcing
Myriad's patents to stop the researchers from using the BRCA1
and BRCA2 sequences to develop their own screening tests, the
testing for BRCAl/2 mutations was performed at a third of
Myriad's costs. 210 Because the sequences are a product of nature, a
patent on them effectively removed the sequences from the public
domain and researchers' use though the sequences technically had
always existed in the public domain long before Myriad filed its
patents with the USPTO.
Justice Breyer credits the "products of nature" exception as
integral in preventing researchers from forcibly having "to avoid
the use of potentially patentable ideas." This fundamental feature
is the same one that made sure that Newton could not patent the
law of gravity and "Einstein could not patent his celebrated
E=mc 2 "211
The importance and necessity of having a patent
208. Myriad's patent enforcement did limit the access to the genetic test as
evidenced by Plaintiff scientists and physicians that ceased offering BRCAl and
BRCA2 analysis in research studies for fear of patent infringement liability.
Ass'n for Molecular Pathology, 2010 U.S. Dist. LEXIS 35418, at *6(-64.
Researchers have published a number of case studies and surveys on clinical
genetic testing indicating that clinical genetics testing laboratories have removed
certain tests from their available services or have chosen not to set up particular
genetic tests because of gene patent issues. Ledbetter, supra note 89, at 314.
See Mildred K. Cho et al., Effects of Patents and Licenses on the Provision of
ClinicalGenetic Testing Services, J. MOLECULAR DIAGNOSTICS 3 (2003).
209. Myriad sent cease and desist letters to Dr. Kazazian, Dr. Oster, Dr.
Weber, and the Yale DNA Diagnostic Lab. See Ass'nfor MolecularPathology,
2010 U.S. Dist LEXIS 35418, at *61-65.
210. Williams- Jones, supra note 42, at 142. The Hereditary Cancer Program
at the B.C. Cancer Agency performed genetic testing at approximately C$ 1200
while the Myriad test cost C$ 3850. Id
211. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
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system where limits exist is essential to the proliferation of
continued innovation. The impediments the BRCAl/2 patents
caused on researchers, such as the inability to research certain
topics when the natural sequences were taken out of the public
domain, were therefore foreseeable by the justifications for the
"products of nature" exception.
Further, Myriad's patents led to another negative consequence
when Myriad tried to establish "complex licensing agreements" for
use of the BRCAl/2 patents to the detriment of other
researchers.2 12 Because the BRCAl/2 patents are directed to
''products of nature," complex licensing agreements impeded the
"free exchange of information" 213 when Myriad offered only
limited collaborative licensing agreements that ran the risk of
underutilizing researchers' abilities and retarding the advancement
of knowledge of BRCAl/2.214 For example, the full spectrum of
cancers caused by or associated with BRCAl/2 gene mutations is
unknown but suspected to stretch beyond the already identified
breast, ovarian, prostate, and pancreatic cancer risks. 215 Therefore,
while Myriad enforced its patents against potentially infringing
researchers, the full spectrum of the cancer risks associated with
BRCAl/2 mutations remained unknown because Myriad forced
the end of all research into such matters.2 16
Finally, the patents impeded the free exchange of information
where their enforcement served to raise the cost of using the
patented information by disabling and in some instances
prohibiting the use all together. 2 17 As the patent holder, Myriad
rightfully precluded other companies from developing their own
BRCAl/2 mutation-screening tests. Throughout the term of the
212. Lab. Corp., 548 U.S. at 126-27 (Breyer, J., dissenting over the dismissal
of certiori).
213. Id.
214. Myriad also tried to establish collaborative licenses with research
institutes but failed because the license terms were too limited as to the
researchers' permitted use of the patents. Ass'n for Molecular Pathology, 2010
U.S. Dist LEXIS 35418, at *61-65.
215. Zielinski, supra note 153.
216. Id.
217. Lab. Corp., 548 U.S. at 126-27 (2006) (Breyer, J., dissenting over the
dismissal of certiori).
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patents, Myriad never licensed out its diagnostic tests to other
laboratories; therefore, Myriad's BRACAnalysis test was the only
available option in the United States for a patient seeking to screen
for mutations in his or her BRCAl or BRCA2 sequences.218 As a
consequence of Myriad being the sole diagnostic laboratory to
analyze a person's BRCAl/2 genetic sequence, it was impossible
for a patient to obtain a second opinion independent of the Myriad
test result. 2 19 While in some medical settings a second opinion can
be superfluous or a waste of resources, the invasive actions
sometimes necessitated by a positive result for a BRCAl or
BRCA2 mutation warrant the availability of a second opinion. 220
The Southern District of New York should have noted that these
foreseeable dangers are avoidable in a patent system that adheres
to the "products of nature" exception.
B. FutureImplications
The Southern District of New York failed to align Plaintiffs'
testimony of the harms caused by Myriad's enforcement of its
patents with the justification for the "products of nature"
exception. The court improperly neglected Justice Breyer's
dissent over the dismissal of Laboratory Corporation of America
Holdings v. Metabolite Laboratories,Inc. that foresaw some of
these exact harms. By not aligning the evidence of the social
218. Ass'n for Molecular Pathology v. USPTO, No. 09-4515, at 36
(S.D.N.Y. Nov. 2, 2009) (order denying motion to dismiss), available at
http://docs.justia.com/cases/federal/district-courts/new-york/nysdce/
1:2009cv04515/345544/140/.
219. Ass'nfor MolecularPathology, 2010 U.S. Dist. LEXIS 35418, at *15.
220. Cook-Deegan, supra note 13, at S26 (surgeries include prophylactic
mastectomy, prophylactic salpingo-oophorectomy or tubal ligation). For those
testing positive, a second opinion and confirmation would be desirable before
embarking on cancer prevention steps that can include more frequent cancer
screenings and even surgery. Id. Not being able to obtain a second test because
an insurance provider will not pay for another $3000 Myriad screening when
less expensive screening exams do exist has the potential to harm patients'
abilities to participate in informed decision-making, an important factor in
deciding whether to undergo invasive prophylactic surgery to significantly
decrease the chances of developing cancer from the BRCAl/2 gene mutation.
Id.
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harms caused by the patents with the justification for the "products
of nature" exception, the court perpetuates the fallacy that
statutory patent law is not equipped to consider social policy
arguments. Making such a statement would have at least garnered
some sense that the American patent law system, guiding the
practices of the USPTO, was not intended to legally permit the
grant of patents that so clearly caused so much harm to researchers
and at risk-patients.
Where the arms of government continually fail to properly
address the needs of society, particularly where Constitutional
undertones shade the debate, courts are essential in resolving
complex policy-based issues. For that matter, the USPTO has
certainly failed in its own attempts to clarify this impasse. In
2001, the USPTO issued Utility Guidelines that included responses
to comments made against its policy of granting patents on DNA
sequences.2 2 1 While the guidelines served as a comprehensive
affirmation of the USPTO practices, they did not directly address
or put at ease the arguments against the practice of granting patents
on sequenced genes.222 In the 2001 Utility Guidelines, the USPTO

221. 2001 USPTO Guidelines, supra note 96, at 1092. The guidelines are to
be used by the USPTO personnel in their "review of patent applications for
compliance with the 'utility' requirement of 35 U.S.C. § 101." Id. at 1092.
222. See id. "Several comments stated that DNA should be freely available
for research. Some of these comments suggested that patents are not necessary
to encourage additional discovery and sequencing of genes. Some comments
suggested that patenting of DNA inhibits biomedical research by allowing a
single person or company to control use of the claimed DNA. Another
comment expressed concern that patenting ESTs will impeded complete
characterization of genes and delay or restrict exploration of genetic materials
for the public good." Id. at 1095, cmt. 12. As stated in the January 2007
Congressional RS Reports, patents certainly are needed to protect innovation
because the costs associated with imitating a product are extremely low
compared with the inventor's costs. Cong. Research Serv., supra note 87, at
CRS-2. However, the court did not discuss how or if patents on gene-related
inventions work to promote innovation by protecting investments made in the
innovation process. Ass'n for Molecular Pathology, 2010 U.S. Dist. LEXIS
35418, at *20-21. The court further did not address the argument that patent
exclusivity is a requirement in the development of personalized medicine and
that a wholesale abolition on patents on isolated DNA sequences is undesirable
as public policy. Id. at *22, 24.
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admitted to strictly administering the laws as enacted by Congress
and interpreted by the federal courts to work within the scope of
subject matter that is patentable.223 Just as the USPTO has failed to
address the policy concerns brought up against the practice of
granting patents on isolated DNA, so has the Southern District of
New York in Associationfor Molecular Pathologyv. USPTO.
Plaintiffs' arguments that isolated DNA falls under the
"products of nature" exception to patentable subject matter were
the same rejected arguments that littered the 2001 Utility
Guidelines. These arguments previously had little effect on
altering the USPTO's course of action as evidenced in the
responses to the comments presented in the 2001 Utility
Guidelines. 224 This inconsistency rightfully leaves one to wonder
exactly what value can such policy arguments hold in future cases.
As noted in the decision, the USPTO granted these patents
pursuant to a formal written policy that permitted the patenting of
isolated and purified DNA encoding human genes. 225 The written
policy described the USPTO's policy to only allow claims to DNA
that had been isolated or purified.226 Similar to the Associationfor
Molecular Pathology decision, this written formal policy of
granting patents on DNA sequences like the patents on the BRCAl
and BRCA2 sequences held by Myriad never formally addressed
the history or justifications for the "products of nature" exception
to patentable subject matter.
If, however, the "products of
nature" exception were to be framed as a rule rooted in
constitutional necessity for the protection and betterment of
society, the task of incorporating policy arguments in patent case
decisions and USPTO guidelines would become much more
223. 2001 USPTO Guidelines supra note 96, at 1095 response to cmt. 12
("Congress creates the law and the Federal judiciary interprets the law. The
USPTO must administer the laws as Congress has enacted them and as the
Federal courts have interpreted them.").
224. See id
225. Ass'n for Molecular Pathology, 2010 U.S. Dist LEXIS 35418, at *83,
n.25. The policy permits the issuance of patents on DNA sequences and the
correlations created by nature between natural elements of the body and a
predisposition to disease. Id.
226. 2001 USPTO Guidelines, supra note 96, cmt. 2 at 1093.
227. Id. at 1095, response to cmt. 12.
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feasible.
C. PossibleActions Through Appeals and Licensing Changes
By leaving these policy issues unaddressed, the court makes it
impossible to judge whether any weight ought to be given to
policy arguments or whether such arguments should instead be
This opinion
flatly rejected and ignored in future cases.
perpetuates the continuation of a long history of judicial precedent
that has failed to strike a proper balance in what Justice Kennedy
identified in Bilski between protecting inventors and preventing
monopolies.228
If this case is appealed, it may be that the reviewing court will
similarly find that the BRCAl and BRCA2 genes are products of
nature on the same grounds as the Southern District of New York,
upholding the decision and again never discussing the policy
arguments and alleviating the societal concerns raised by
Plaintiffs. Even if on appeal a court finds that isolated DNA is
instead not a product of nature, as Myriad argues, and reverses the
invalidation on § 101 grounds for subject matter, addressing the
societal harms can still work to give bite to the IP Clause. The
gene patents can be declared unconstitutional, as Plaintiffs argue,
under the IP Clause on the grounds that "the patent claims in this
case can be held as a matter of law to impede rather than promote
the progress of science."229 As with the policy reasons behind the
"products of nature" exception discussed above, an assessment
under the IP Clause would be a long overdue opportunity for a
228. Bilski v. Kappos, 130 S. Ct. 3218, 3228 (2010). "With ever more
people trying to innovate and thus seeking patent protections for their
inventions, the patent law faces a great challenge in striking the balance between
protecting inventors and not granting monopolies over procedures that others
would discover by independent, creative application of general principles.
Nothing in this opinion should be read to take a position on where that balance
ought to be struck." Id.
229. Myriad Defendant's Memorandum of Law (1) In Support of their
Motion for Summary Judgment and (2) In Opposition to Plaintiffs' Motion for
Summary Judgment, Ass'n for Molecular Pathology v. USPTO, No. 09-4514, at
5 (S.D.N.Y. filed December 23, 2009), available at http://docs.justia.com/
cases/federal/district-courts/new-york/nysdce/1:2009cv04515/345544/153/.
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court to strike a balance and determine just how much impediment
to the progress of science is enough to invalidate a patent.
In the meantime, this ruling could even encourage Congress to
step in and say that while patents on isolated DNA are valid, their
use must be reformed. For instance, the National Institute of
Health and the Association of University Technology Managers
strongly encourage nonexclusive licensing strategies except in
cases where this model will not lead to successful
commercialization.230 In the cases of genetic testing, nonexclusive
licensing strategies have the significant advantages of encouraging
multiple laboratories to make the test readily available.23 ' This
encourages test improvement and creates cost-competition,
addressing two of the arguments made by those against patents on
isolated DNA.232
Investigators at academic institutions could instead be forced to
adopt a policy that allows multiple clinical laboratories to offer
genetic testing on any new genes discovered and patented.233 The
success of such a compromise, however, is uncertain as the
American College of Medical Genetics has an official position
against genetic patenting.234
The large reach of this decision is vulnerable to a significant
number of challenges from patent holders, wanting a return on any
time, money, and resources invested and intent on maintaining
their patents as a means to further profit off their work. The 2008
CRS Report published that as of the end of fiscal year 2007, the
USPTO had issued more than 49,000 patents related to genes,
including method of use. 235 The status of these patents on isolated
DNA is at most uncertain after the invalidation of Myriad's
BRCAl and BRCA2 patents. However, to hand down such a
definitive ruling to invalidate all patents direct to isolated DNA,
the court should have addressed the societal concerns in line with
the policy justification for the products of nature exception to give

230.
231.
232.
233.
234.
235.

See Ledbetter, supra note 89, at 316, 318.
Id. at 317.
Id. at 315.
Id.
Id. at 314.
Cong. Research Serv., supra note 87, at CRS-2.
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value to the concerns moving forward.
A discussion of how the social harms weighed in the decision
against Myriad may never happen. In an amicus brief filed by the
United States Department of Justice in support of neither party of
this case, the support to invalidate the BRCAl and BRCA2 patents
was again limited to only a statutory discussion on patentable
subject matter. 236 This briefs potential influence in the case's
appeal will likely maintain the opinion's resolution through
technical means and leave out any discussion of the social harms,
ultimately perpetuating the notion that patent law is too inflexible
to account for the prevention of such harms. The Southern District
of New York's opinion would in due course be just another
application of the "products of nature" exception having missed
the opportunity to incorporate the evidence of societal harm to
invalidate a patent.
V. CONCLUSION

The Southern District of New York's opinion in Association for
Molecular Pathology v. USPTO thoroughly described the societal
harms associated with the patents granted on the BRCAl and
BRCA2 genetic sequences. The court's holding does prevent
additional societal harm: researchers now have legal access to the
BRCAI and BRCA2 gene sequences as a means to develop more
accurate, efficient, and affordable screening tests to ensure
adequate access for high-risk cancer patients. The court's ability
to achieve this goal, however, did not justify the lack of discussion
of how these societal concerns influenced the bright line rule to
invalidate all patent claims directed at isolated DNA sequences.
The court's decision to create a bright line rule, invalidating all
isolated DNA patents on 35 U.S.C § 101 grounds, lends itself to
appeal proceedings and leaves vulnerable significant and valid
arguments made by Plaintiffs against patents on 2 sequences that
ultimately did more harm than good. The absence of such
236. Brief for the United States as Amicus Curiae in Support of Neither
Party, Association for Molecular Pathology, No. 09-4515, available at
http://www.genomicslawreport.com/index.php/tag/department-of-justice/ (filed
Oct. 29, 2010).
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discussion by the court leaves one to wonder how valid these other
arguments focusing on the harm caused by patents really are and
how future courts will handle these other arguments. The judiciary
is not powerless, having itself created the "products of nature"
exception that has continued to hold up in patent law. As such, it
should not find itself now powerless to apply the policies that
necessitated the creation of the exception to invalidate patents.
Until appeals or additional cases are heard, the legitimacy of
Myriad's patents is still debatable along with the future of all
previously valid isolated DNA patents.
Lamis G. Eli
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